This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Olink Holding Résultats passés
Passé contrôle des critères 0/6
Olink Holding has been growing earnings at an average annual rate of 8%, while the Life Sciences industry saw earnings growing at 16.8% annually. Revenues have been growing at an average rate of 31.7% per year.
Informations clés
8.0%
Taux de croissance des bénéfices
85.3%
Taux de croissance du BPA
| Life Sciences Croissance de l'industrie | 21.5% |
| Taux de croissance des recettes | 31.7% |
| Rendement des fonds propres | -7.3% |
| Marge nette | -19.7% |
| Dernière mise à jour des bénéfices | 31 Mar 2024 |
Mises à jour récentes des performances passées
Recent updates
Revenues Tell The Story For Olink Holding AB (publ) (NASDAQ:OLK)
Jun 21
Olink Holding AB (publ) (NASDAQ:OLK) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 28Is It Time To Consider Buying Olink Holding AB (publ) (NASDAQ:OLK)?
Oct 19We're Interested To See How Olink Holding (NASDAQ:OLK) Uses Its Cash Hoard To Grow
Jul 04A Look At The Intrinsic Value Of Olink Holding AB (publ) (NASDAQ:OLK)
Jun 13At US$21.02, Is It Time To Put Olink Holding AB (publ) (NASDAQ:OLK) On Your Watch List?
May 23Olink Holding (NASDAQ:OLK) Is In A Strong Position To Grow Its Business
Mar 20Calculating The Intrinsic Value Of Olink Holding AB (publ) (NASDAQ:OLK)
Dec 31Olink Holding partners with Discovery Life Sciences to establish commercial platform
Sep 20We're Hopeful That Olink Holding (NASDAQ:OLK) Will Use Its Cash Wisely
Sep 16Olink GAAP EPS of -$0.04, revenue of $27.5M; reaffirms FY22 guidance
Aug 11We're Not Very Worried About Olink Holding's (NASDAQ:OLK) Cash Burn Rate
May 16Olink Holding Plans Strong 2022 Spending Amid Growth Slowdown
May 13Olink Holding AB (publ) (NASDAQ:OLK) Just Reported, And Analysts Assigned A US$29.75 Price Target
Feb 17Companies Like Olink Holding (NASDAQ:OLK) Can Afford To Invest In Growth
Jun 25Ventilation des recettes et des dépenses
Comment Olink Holding gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 171 | -34 | 135 | 38 |
| 31 Dec 23 | 170 | -32 | 130 | 34 |
| 30 Sep 23 | 159 | -19 | 114 | 29 |
| 30 Jun 23 | 147 | -18 | 107 | 27 |
| 31 Mar 23 | 145 | -15 | 103 | 27 |
| 31 Dec 22 | 140 | -13 | 99 | 26 |
| 30 Sep 22 | 126 | -30 | 95 | 28 |
| 30 Jun 22 | 114 | -35 | 92 | 26 |
| 31 Mar 22 | 104 | -36 | 87 | 24 |
| 31 Dec 21 | 95 | -43 | 81 | 22 |
| 30 Sep 21 | 78 | -27 | 70 | 16 |
| 30 Jun 21 | 70 | -26 | 57 | 13 |
| 31 Mar 21 | 60 | -28 | 44 | 11 |
| 31 Dec 20 | 54 | -24 | 33 | 10 |
| 31 Dec 19 | 46 | -37 | 45 | 7 |
Des revenus de qualité: OLK is currently unprofitable.
Augmentation de la marge bénéficiaire: OLK is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: OLK is unprofitable, but has reduced losses over the past 5 years at a rate of 8% per year.
Accélération de la croissance: Unable to compare OLK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: OLK is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-6.5%).
Rendement des fonds propres
ROE élevé: OLK has a negative Return on Equity (-7.3%), as it is currently unprofitable.